Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

Overview of attention for article published in Leukemia & Lymphoma, July 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 26,017 followers.

RT @prajwal_dhakal: Great presentation from Emily Curran regarding use of Immuntherapy in R/R ALL. @SocietyofHemOnc Similar review from ou…

Great presentation from Emily Curran regarding use of Immuntherapy in R/R ALL. @SocietyofHemOnc Similar review from our team may add some info! https://t.co/9lNDS7SScC #SOHO2020 #Leukemia #ALL https://t.co/1J5KRwbRRY

Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents? #lymphoma #lymsm https://t.co/KzuXo3XcWo

Our attempt to discuss #immunotherapy for R/R #ALL #acutelymphoblasticleukemia #leukemia. Would love your feedback. https://t.co/LPVwJ9ZUxm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.